Prognostic significance of leukopenia during the induction phase in adult B cell acute lymphoblastic leukemia

References

• FaderlSO’BrienSPuiCHAdult acute lymphoblastic leukemia: concepts and strategiesCancer201011651165117620101737
   PubMed Web of Science ®Google Scholar
• BassanRHoelzerDModern therapy of acute lymphoblastic leukemiaJ Clin Oncol201129553254321220592
   PubMed Web of Science ®Google Scholar
• RoweJMBuckGBurnettAKInduction therapy for adults with acute lymphoblastic leukemia: results of >1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993Blood2005106123760376716105981
   PubMed Web of Science ®Google Scholar
• HoelzerDThielELofflerHPrognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adultsBlood19887111231313422030
   PubMed Web of Science ®Google Scholar
• LeQHThomasXEcochardRInitial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemiaEur J Haematol200677647147916978239
   PubMed Web of Science ®Google Scholar
• BaccaraniMCorbelliGAmadoriSAdolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy. A study of 293 patientsBlood19826036776846954995
   PubMed Web of Science ®Google Scholar
• KvinnslandSThe leucocyte nadir, a predictor of chemotherapy efficacy?Br J Cancer19998011168110468282
   PubMed Web of Science ®Google Scholar
• IyerLRatainMJPharmacogenetics and cancer chemotherapyEur J Cancer19983410149314999893619
   PubMed Web of Science ®Google Scholar
• EvansWECromWRStewartCFMethotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemiaLancet1984183733593626141424
   PubMed Web of Science ®Google Scholar
• SaartoTBlomqvistCRissanenPAuvinenAElomaaIHaematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancerBr J Cancer19977523013059010042
   PubMed Web of Science ®Google Scholar
• PoikonenPSaartoTLundinJJoensuuHBlomqvistCLeucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMFBr J Cancer199980111763176610468293
   PubMed Web of Science ®Google Scholar
• MayersCPanzarellaTTannockIFAnalysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinomaCancer200191122246225711413512
   PubMed Web of Science ®Google Scholar
• CameronDAMassieCKerrGLeonardRCModerate neutropenia with adjuvant CMF confers improved survival in early breast cancerBr J Cancer200389101837184214612889
   PubMed Web of Science ®Google Scholar
• HorwichASleijferDTFossaSDRandomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic non-seminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer TrialJ Clin Oncol1997155184418529164194
   PubMed Web of Science ®Google Scholar
• RankinEMMillLKayeSBA randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancerBr J Cancer19926522752811739629
   PubMed Web of Science ®Google Scholar
• PallisAGAgelakiSKakolyrisSChemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapyLung Cancer200862335636318501466
   PubMed Web of Science ®Google Scholar
• BrosteanuOHasencleverDLoefflerMDiehlVLow acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin’s diseaseAnn Hematol200483317618215064867
   PubMed Web of Science ®Google Scholar
• GurneyHHow to calculate the dose of chemotherapyBr J Cancer20028681297130211953888
   PubMed Web of Science ®Google Scholar
• SchmiegelowKHeymanMGustafssonGThe degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapseLeukemia201024471572020130603
   PubMed Web of Science ®Google Scholar
• ShiozawaYTakitaJKatoMPrognostic significance of leukopenia in childhood acute lymphoblastic leukemiaOncol Lett2014741169117424944687
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network: Fort Washington, USAAcute Lymphoblastic Leukemia, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Version 12014
   Google Scholar
• An International System for Human Cytogenetic Nomenclature (1985) ISCN 1985. Report of the Standing Committee on Human Cytogenetic NomenclatureBirth Defects Orig Artic Series19852111117
   Google Scholar
• WetzlerMCytogenetics in adult acute lymphocytic leukemiaHematol/Oncol Clin N Am200014612371249
   PubMed Web of Science ®Google Scholar
• PullarkatVSlovakMLKopeckyKJFormanSJAppelbaumFRImpact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 studyBlood200811152563257218156492
   PubMed Web of Science ®Google Scholar
• MoormanAVHarrisonCJBuckGAKaryotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trialBlood200710983189319717170120
   PubMed Web of Science ®Google Scholar
• StanullaMSchrappeMTreatment of childhood acute lymphoblastic leukemiaSemin Hematol2009461526319100368
   PubMed Web of Science ®Google Scholar
• HanHSRybickiLAThielKWhite blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemiaLeuk Lymphoma20074881561156817701588
   PubMed Web of Science ®Google Scholar
• ConterVBartramCRValsecchiMGMolecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 studyBlood2010115163206321420154213
   PubMed Web of Science ®Google Scholar
• BrandaliseSRPrognostic value of day 8 peripheral blood response for children with acute lymphocytic leukemiaZanderARGene Technology: Stem Cell and Leukemia ResearchBerlinSpring-Verlag1996421428
   Google Scholar
• PreislerHDGessnerTAzarniaNRelationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemiaCancer Chemother Pharmacol19841221256697426
   PubMed Web of Science ®Google Scholar
• RodmanJHAbromowitchMSinkuleJAHayesFARiveraGKEvansWEClinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trialJ Clin Oncol198757100710143598607
   PubMed Web of Science ®Google Scholar
• EvansWECromWRAbromowitchMClinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effectN Engl J Med198631484714773456079
   PubMed Web of Science ®Google Scholar
• GurneyHDose calculation of anticancer drugs: a review of the current practice and introduction of an alternativeJ Clin Oncol1996149259026118823340
   PubMed Web of Science ®Google Scholar
• HassanMSvenssonUSLjungmanPA mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patientsBr J Clin Pharmacol199948566967710594468
   PubMed Web of Science ®Google Scholar
• SparreboomAWolffACMathijssenRHEvaluation of alternate size descriptors for dose calculation of anticancer drugs in the obeseJ Clin Oncol200725304707471317947717
   PubMed Web of Science ®Google Scholar
• SulkesACollinsJMReappraisal of some dosage adjustment guidelinesCancer Treat Rep19877132292333815390
   PubMedGoogle Scholar
• EkhartCRodenhuisSSmitsPHBeijnenJHHuitemaADAn overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatmentCancer Treat Rev20093511818771857
   PubMed Web of Science ®Google Scholar
• CherianSLevinGLoWYEvaluation of an 8-color flow cytometric reference method for white blood cell differential enumerationCytometry B Clin Cytom201078531932820533390
   PubMedGoogle Scholar
• YuCKongQLZhangYXClinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemiaJ Hematol Oncol2015814825957890
   PubMedGoogle Scholar
• BruggemannMRaffTKnebaMHas MRD monitoring superseded other prognostic factors in adult ALL?Blood2012120234470448123033265
   PubMed Web of Science ®Google Scholar